Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients

Table 1 Effect of CYP3A4*1B single nucleotide polymorphism on tacrolimus pharmacokinetics

Ref.	Study population	Transplant type/analysis of recipients, donors or both	Findings
Cho et al[84]	70 Korean	Kidney recipients	No association between CYP3A4*1B genotype and tacrolimus dose requirements up to 6 mo after transplantation
Roy et al[85]	38 Caucasian,4 Black,2 Asian	Kidney recipients	No correlation between the CYP3A4*1B SNP and tacrolimus pharmacokinetic at first week and third month after transplantation
Hesselink et al[67]	37 Caucasian,9 Black,18 Asian	Kidney recipients	CYP3A4*1B allele carriers had lower tacrolimus dose-adjusted trough levels with respect to patients carrying the wild-type (*1/*1) genotype at third and 12th month after transplantationThis effect was not observed when analyzing only the Caucasian population.
Hesselink et al[87]	120 Caucasian, 7 Black,8 Asian,1 other	Kidney recipients	No significant correlation observed between CYP3A4*1B SNP and tacrolimus pharmacokinetics when CYP3A5 and ABCB1 SNPs were taken into account
Gervasini et al[33]	103 Spanish	Kidney recipients	Carriers of the CYP3A4*1B variant allele had 59% lower tacrolimus concentrations than those with CYP3A4*1/*1 wild type genotypeAll CYP3A4*1B carriers were also carriers of CYP3A5*1 allele (linkage disequilibrium)